OMED Health, a UK-based company developing non-invasive breath analysis tools for gut health and part of Owlstone Medical, has launched a new service offering personalized care for patients with functional gastrointestinal (GI) conditions. The new “OMED Health Plans” combine at-home diagnostics, clinical support, and tailored treatment pathways to address a market estimated to include more than one billion people globally.

Initially available in Great Britain, OMED Health Plans include at-home breath testing for Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), powered by OMED’s proprietary Breath Analyzer device. These tests are combined with clinician-led care, including nutritional support (such as FODMAP protocols), therapeutic interventions, and one-to-one clinical consultations.

The launch builds on Owlstone Medical’s broader Breath Biopsy® platform, aiming to move chronic GI care from hospitals to communities, reduce costs, and provide more personalized solutions.

“Digestive health is one of the largest untapped opportunities in consumer-facing diagnostics and chronic disease management,” said Billy Boyle, CEO and Co-founder of Owlstone Medical. “Through the expanded OMED offering, patients with functional GI conditions will for the first time be able to access end-to-end, clinician-led, and evidence-based treatment plans utilizing longitudinal breath monitoring, optimized specifically for them based on their breath profiles.”

Feedback from participants in OMED pilot programs has been positive, with many reporting significant improvements in digestive health following a diagnosis of SIBO or IMO and subsequent treatment using the Breath Analyzer.

Boyle added, “Owlstone is building a category-defining platform through OMED Health at the intersection of diagnostics, digital health, therapeutics, and personalized care. With recurring revenue potential, robust unit economics, and a vast addressable market, OMED is well positioned to address a major gap in chronic GI care, enabling rapid growth by providing effective, evidence-based GI care at scale. Beyond the significant opportunity in Great Britain, there is large upside potential through expansion to other markets through strategic partnerships and licensing.”

OMED plans to offer its new service both through healthcare providers and directly to consumers, supporting a growing trend toward non-invasive diagnostics and tailored treatment.